Introduction
Renal cell carcinoma (RCC) is characterized by highly vascularized tumors that are dependent on angiogenic pathways (1) . The vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pathways are key drivers of angiogenesis. These pathways can be activated by the transcription factor hypoxiainducible factor (HIF), a protein normally degraded by an E3 ubiquitin-ligase complex containing the von Hippel Lindau (VHL) protein, a tumor suppressor commonly inactivated in clear cell RCC. Tyrosine kinase inhibitors (TKIs) of the VEGF and PDGF pathways, such as sorafenib, sunitinib, pazopanib, and axitinib, are given for advanced disease (2) (3) (4) (5) . The mammalian target of rapamycin (mTOR) is a central regulator of multiple processes in RCC, including angiogenesis, tumor cell proliferation, and protein metabolism, and the mTOR inhibitor everolimus has also shown activity in this patient population (6) . Together, VEGF, PDGF, and mTOR inhibitors have demonstrated a median overall survival of up to 29 months in patients with previously untreated metastatic RCC (mRCC; ref. 7, 8) .
The majority of patients with mRCC become resistant or are refractory to angiogenesis inhibitors, including the TKIs and the anti-VEGF monoclonal antibody bevacizumab (9, 10) . . Mechanisms of resistance include enhancement of receptor signaling to overcome target inhibition, upregulation of HIF following tumor VEGF blockade, tumor hypoxia leading to proangiogenic signaling, upregulation of mTOR complex 2 (which also leads to HIF activation), or activation of alternative angiogenic pathways (1, 11) . In addition to VEGF and PDGF, the fibroblast growth factor (FGF) pathway has been shown to play an important role in tumor angiogenesis (12, 13 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 21, 2013; DOI: 10.1158/1078-0432.CCR- example, highly vascularized tumors often contain high levels of FGFs and FGF receptors (FGFRs) after treatment with VEGF pathway inhibitors (14) . In addition, dysregulated expression of FGFs or FGFRs has been described in several cancers, including RCC (15) . Preclinical studies also show that FGF signaling is a possible mechanism of escape from and resistance to anti-VEGF therapy (16) . Therefore, inhibition of FGF and VEGF signaling may provide additional benefit compared with inhibition of VEGF signaling alone (11) .
Dovitinib is a potent, oral inhibitor of receptor tyrosine kinases, including FGFR1
(IC 50 8 nM), FGFR2 (IC 50 40 nM) and FGFR3 (IC 50 9 nM), as well as VEGF receptor (VEGFR) 1 to 3, and PDGF receptor (PDGFR) β ( IC 50 < 40 nM; (17) that has shown antitumor and antiangiogenic effects in preclinical models of colon, breast, bladder, pancreatic, and renal cell cancers (18) (19) (20) (21) (22) (23) ). Here we demonstrate antitumor activity in preclinical models of RCC and report on the dose-escalation portion of a phase I/II study (NCT00715182) to identify the maximum tolerated dose (MTD) of dovitinib on a 5-days-on/2-days-off dosing schedule in repeating 28-day cycles (starting dose, 500 mg) in patients with advanced RCC or mRCC refractory to standard therapies. The phase II portion of this study (24) will be reported separately.
Materials and Methods

Preclinical RCC model
In separate, single experiments, female Harlan nude mice were subcutaneously 
Clinical trial design
This report presents data from the phase I, dose-escalation portion of a multicenter, open-label, phase I/II study (NCT00715182). The primary objective of the dose-escalation phase was to determine the MTD of dovitinib based on incidence of dose-limiting toxicity (DLT) in patients with RCC who had progressed despite standard therapy. Decisions regarding dose escalation were made by overall assessment of the clinical, safety, pharmacokinetic, and pharmacodynamic data in conjunction with the recommendations of the Bayesian logistic regression model guided by the escalation with overdose control principle (25). Cohorts could be expanded for further safety and pharmacokinetic assessments. Secondary objectives included evaluations of safety and preliminary antitumor activity of the dose and administration schedule. Exploratory objectives included evaluation of plasma and tumor biomarkers to monitor the pharmacodynamic effect of oral dovitinib inhibiting FGFR and VEGFR in advanced RCC and assessment of resistance to prior antiangiogenesis therapies. Dovitinib was administered orally at a dose of 500 or 600 mg/day on a 5-dayson/2-days-off schedule in 28-day cycles. This intermittent schedule was selected Patients continued treatment until disease progression or unacceptable toxicity. The study protocol was reviewed and approved by each site's institutional review board, independent ethics committee, or research ethics board. All patients provided written consent. The trial was conducted in accordance with the ICH Harmonised Tripartite Guideline for Good Clinical Practice, applicable local regulations, and the ethical principles in the Declaration of Helsinki.
Patients
Patients with advanced or metastatic RCC with predominant clear cell histology were eligible for this study. Other eligibility criteria include: age ≥18 years, Eastern Cooperative Oncology Group performance status ≤1, life expectancy ≥12 weeks, absolute neutrophil count ≥1.5 × 10 9 /L, platelets ≥75 × 10 9 /L, hemoglobin ≥80 g/L, serum creatinine ≤1.5 × upper limit of normal, and bilirubin ≤1.5 × upper limit of normal.
Patients with brain metastases were eligible. Patients with clinically significant cardiac disease (including New York Heart Association Class III or IV) or impaired cardiac function were excluded from the trial. Other exclusion criteria included diabetes mellitus with signs of clinically significant peripheral vascular disease, pancreatitis, liver disease, chronic liver impairment, major surgery within 28 days, prior pericarditis, clinically significant pleural effusion within 12 months, and current ascites requiring 2 or more interventions/month. Medications with a potential risk of prolonging the QT interval or inducing torsades de pointes had to be discontinued prior to starting study drug. Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin, or quinidine within 2 weeks prior to baseline was also excluded due to potential drug-drug interactions.
Assessments
Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events v3.0. A DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications occurring within cycle 1 (see Supplemental Table 1 
Pharmacodynamic analysis
Research. Values below the lower limit of quantification were set to half of the lower limit of quantification value. Fold-change was computed by subtracting log 2 -transformed cycle 1 day 1 values from cycle 1 days 15 and 26 values and was assessed using a 1-way linear mixed-effects model with time as the main effect and applying a false discovery rate adjustment to the P values.
Tumor biopsies, if available, were obtained at baseline and within 6 hours of dosing on cycle 1 day 15 or per investigator-determined posttreatment day. Tumor cells were stained for phosphorylated ERK (pERK) using rabbit anti-pErk monoclonal 20G11 and mouse anti-CD31 monoclonal antibody (Cell Signaling Technology; 1 μg/ml) on an immunostainer (Ventana Medical Systems, Inc.) as previously described (27) .
Results
Preclinical RCC model
To determine whether inhibition of the FGF, VEGF, and PDGF pathways could provide additional benefit compared with inhibition of VEGF and PDGF pathways alone, (Fig. 1A) . Dovitinib demonstrated dose-dependent antitumor activity, with 91% reduction in mean tumor volume in treated mice compared with vehicle. Dovitinib activity in RCC xenograft models was also tested using Caki-1 tumors, which induce high plasma concentrations of VEGF that correlate with tumor size, thereby offering a good model for testing antiangiogenic agents (29). In the Caki-1 model, sunitinib and sorafenib induced 66% and 16% reductions in mean tumor volume, respectively, compared with vehicle, whereas dovitinib demonstrated 83% reduction in mean tumor volume. Taken together, these data demonstrate that dovitinib has antitumor activity in RCC models and was as at least as effective as 2 clinically approved TKIs at their MTDs.
Patient demographics and disposition
A clinical trial of dovitinib was conducted in RCC patients who had progressed despite standard therapy. Twenty patients with a median age of 55.5 years (range, 29-71) were enrolled in phase I of the study between July 3, 2008, and November 9, 2010, and received at least 1 dose of dovitinib at either 500 mg (n = 15) or 600 mg (n = 5).
Patients were Caucasian (n = 16; 80.0%) and Asian (n = 3; 15.0%), with 1 patient's race not specified (n = 1; 5%). Thirteen (65.0%) patients were identified as having clear cell carcinoma and 7 (35.0%) patients had histologies incompletely recorded as renal adenocarcinoma; however, source documentation verified that these were clear cell carcinoma. Patients had advanced or metastatic cancer, with a median of 3.5 metastatic sites (range, 1-9), most commonly lung, lymph nodes, and bone (Table 1) (80.0%) patients. All patients discontinued from the study, 13 (65.0%) due to disease progression and 6 (30.0%) due to AE(s); 1 (5.0%) patient withdrew consent.
Determination of MTD
The first 4 patients were enrolled in cohort 1 (500 mg). All patients were evaluable, and 1 DLT (grade 2 sinus bradycardia leading to discontinuation) was reported. The dose for cohort 2 was escalated to 600 mg, and 5 patients were enrolled, with 1 patient not meeting the minimum exposure criteria, leaving 4 patients evaluable for MTD. Two patients in cohort 2 experienced DLTs (grade 4 hypertensive crisis and grade 3 asthenia with grade 2 nausea and vomiting, both leading to discontinuation). On the basis of the Bayesian logistical regression model recommendation and the clinical safety data, a decision was made to treat the patients in cohort 3 (n = 4) with a decreased dosage of 500 mg. All patients in cohort 3 were evaluable for MTD, and no DLTs were observed. Extension cohort 4 included an additional 7 patients treated with 500 mg (all evaluable for MTD), and no DLTs were observed. Upon evaluation of all data, the dose of 500 mg/day on a 5-days-on/2-days-off schedule was declared as the MTD.
Safety
The median duration of exposure was 99 days (range, 1-838 days) for all patients and 116 days (range, 1-838 days) and 68 days (range, 5-187 days) in the 500-and 600-mg cohorts, respectively. Four of the 20 (20.0%) enrolled patients had their dovitinib dose reduced following an AE (3 patients in the 500-mg cohorts and 1 patient in the 600-mg cohort). Eight (53.3%) patients in the 500-mg cohorts and 1 (20.0%) patient in the 600-mg cohort experienced 1 (n = 5, 4 patients in the 500-mg cohorts and Overall, the most common AEs suspected to be related to dovitinib treatment were nausea, diarrhea, vomiting, and asthenia (Table 2) , occurring at 75.0%, 70.0%, 70.0%, and 50.0%, respectively, in all cohorts. The majority of AEs suspected to be related to treatment were mild (grade 1 or 2). The incidences of grade 3 individual gastrointestinal disorders and skin and subcutaneous tissue disorders were all ≤5%, with only grade 3 asthenia occurring at a higher rate (15%). Only 1 grade 4 event occurred; 1 patient in the 600-mg cohort had hypertension (which developed into a serious AE of hypertensive crisis).
Serious AEs suspected to be related to dovitinib treatment were infrequent (n = 3). Two patients with serious AEs, sinus bradycardia (n = 1, a DLT in the 500-mg cohort) and hypertensive crisis with noncardiac chest pain (n = 1, a DLT in the 600-mg cohort) discontinued and their symptoms resolved. The third patient, who experienced pyrexia (600-mg cohort), did not require study drug delay/interruption and later discontinued due to disease progression. Six (30.0%) patients discontinued due to AEs, 4 (26.7%) in the 500-mg cohorts and 2 (40.0%) in the 600-mg cohort. Five of these discontinuations were considered related to study drug: nausea/vomiting, rash, and sinus bradycardia in the 500-mg cohorts and hypertension/hypertensive crisis and nausea/vomiting/asthenia in the 600-mg cohort.
One patient, a 71-year-old man, died during the study. The death on day 389 from pneumonia occurred 4 days after his last dose of study drug (500 mg) and was not suspected to be related to the study drug.
Shifts to grade 4 hematologic abnormalities were not observed, and shifts to grade 3 were infrequent and observed only in the 500-mg cohorts: decrease in absolute lymphocytes (n = 1), decrease in absolute neutrophils (n = 2), decrease in platelet count (n = 1), and decrease in white blood cells (n = 1). These events did not lead to study drug interruption or delay. Shifts to grade 3/4 biochemistry abnormalities were also infrequent and observed only in the 500-mg cohorts. These were grade 3 albumin 
Nineteen patients were evaluated for QT prolongation (1 patient was not on dovitinib long enough to be considered evaluable). Of the QT prolongation events observed, none were reported as AEs. QTcF increase from baseline to >30 ms was observed in 3 (15.8%) patients in the 500-mg cohorts, with 1 of these patients exhibiting an increase >60 ms (from 377 ms predose on day 1 to 439 ms on day 26). QTcF values of 508 and 509 ms were observed in 1 patient predose on days 26 and 43, respectively.
Of note, this patient, who had a high QTcF (484 ms) at screening, continued without dose delay/interruption until disease progression on day 54.
Of 19 evaluable patients, 5 (26.3%) patients, all from the 500-mg cohorts, had newly occurring qualitative ECG abnormalities, most frequently rhythm abnormalities (sinus bradycardia or sinus tachycardia). One patient experienced a DLT, with grade 2 sinus bradycardia on the day of the first dose, 24 hours after normal baseline and predose ECGs, and discontinued from the study. Two of these 5 patients had abnormal baseline ECG findings (flat T waves, and conduction abnormalities and ectopies as firstdegree AV block).
Overall, no clinically significant changes in left ventricular ejection fraction or congestive heart failure were observed in the study. In the 500-mg cohorts, 11 of 15 patients had both baseline and posttreatment echocardiogram (ECHO) (n = 8) and multigated acquisition (MUGA) scans (n = 3). Both ECHO and MUGA scans indicated a slight (<10% mean value) intrapatient decrease in cardiac ejection fractions (ECHO mean change from baseline, −4.6%; range, −13.3% to 2.0%; MUGA mean change from baseline −8.2%; range, −25.5% to 2.0%). One patient (500-mg cohorts) had a MUGA scan decrease from baseline of 71% to 45.5% on day 29 with an overall normal cardiac 
ejection fraction. Subsequent ECHO scans on day 84 and day 141 also showed a normal left ventricular ejection fraction of 60%, and this patient continued with no dose interruption until day 838. Of the 2 patients in the 600-mg cohort who had both baseline and posttreatment ECHO scans, no changes in cardiac ejection fractions were observed.
Efficacy
On the basis of the central radiologist's review, 2 of the 15 (13.3%) patients in the 500-mg cohorts achieved a partial response (PR). Stable disease (SD) was reported in 60.0% of the patients in each cohort (9 and 3 patients in the 500-and 600-mg cohorts, respectively). Disease control lasted for at least 2 months in 11 (73.3%) and 3 (60.0%) patients and at least 4 months in 9 (60.0%) and 2 (40.0%) patients in the 500-and 600-mg cohorts, respectively. Three patients (20.0%) had progressive disease in the 500-mg cohorts, and the remaining 3 patients had unknown or non-assessed response (1 and 2 in the 500-and 600-mg cohorts, respectively).
The best percentage change from baseline in sum of diameters as per central radiological review is shown in Fig. 3 ; 1 patient did not have a valid tumor assessment since no posttreatment scan was done due to early discontinuation from the study after the patient experienced a DLT. Two patients, both receiving 500 mg, achieved longlasting disease stabilization (last confirmed SD response on day 447 and 614). SD was the best response achieved in 2 of the 3 patients presenting with brain metastases at baseline (the third patient had progressive disease) per central review.
Overall, per central review, patients treated at the MTD of 500 mg on a 5-dayson/2 days-off schedule had a median progression-free survival (PFS) of 8.1 months. In these patients, the median overall survival was 13.3 months. In the 600-mg group, 2 patients experienced a DLT and discontinued from the study. The 3 remaining patients in the 600-mg group were dose reduced to 500 mg and had PFS of 1.5, 3.7 and 3.7 months (1 censored due to withdrawal of consent).
Pharmacodynamics
Plasma samples from patients in the 500-mg cohorts were analyzed for VEGF, PlGF, sVEGFR2, and FGF23 levels on days 1 (baseline), 15, and 26 of cycle 1 ( Fig. 2B-E). Elevated plasma FGF23 levels, a surrogate biomarker of FGFR1 inhibition (27), showed a statistically significant increase from baseline on day 15 [110% increase; 95% confidence interval (CI), 28%-143%; P = 0.0131]. VEGFR inhibition was demonstrated via a statistically significant increase in PlGF levels on day 26 (48% increase; 95% CI, 20%-81%; P = 0.0072) and decreases in sVEGFR2 on day 15 (15% decrease; 95% CI, 24%-6%; P = 0.0131) and day 26 (12% decrease; 95% CI, 20%-2%; P = 0.0475).
Although VEGF levels trended upward, they did not reach statistical significance. This may reflect that most of the patients on this trial had received prior anti-VEGF therapies and were less responsive to additional VEGF pathway inhibition.
Two pairs of tumor biopsies were obtained pre-and post-dovitinib treatment (500 mg/day), but only 1 pair was evaluable for immunohistochemical analysis. To confirm inhibition of FGFR and angiogenesis, tumor samples were examined for levels of pERK, a downstream component of FGFR signaling, and CD31 for microvessel density. At day 27 of cycle 4, a noticeable reduction in the expression of pERK and CD31 compared with baseline was observed (Fig. 2F) , indicating that dovitinib inhibits FGFR signaling 
Pharmacokinetics
Pharmacokinetic parameters were similar between the 2 dose cohorts ( Table 3 ).
The maximal concentration was reached in a median of 6 hours in both dose cohorts on cycle 1 day 1. The day 15 geometric mean areas under the plasma concentration-time curve from time 0 to last measurable sampling time for 500 and 600 mg were 30% and 20% lower, respectively, than the day 1 values. Further, t 1/2 decreased from ~23 hours (geometric mean) on day 1 to ~10 hours on day 15 in the 500-mg cohorts. These data are supportive of an autoinduction of CYP1A1/2 by dovitinib following multiple doses.
Discussion
In the study presented here, dovitinib at the MTD of 500 mg on a 5-days-on/2-days-off schedule was generally well tolerated and demonstrated antitumor activity in heavily pretreated patients with mRCC. At this dose, 2 (13.3%) patients achieved PR, and the median PFS and overall survival were 8.1 and 13.3 months, respectively. expected for a TKI in this indication and patient population (2) (3) (4) (5) . Interestingly, doselimiting hyperphosphatemia, a common AE observed with more specific FGFR inhibitors (unpublished, personal observation), was not reported in this study. Additionally, hypertension, a common class effect of the VEGFR pathway inhibitors, was observed at a lower rate than typically observed for this class, a finding that will require larger studies for verification.
In a previous study, dovitinib on a continuous daily dosing schedule led to a prolonged and overproportional increase in dose and exposure above 400 mg/day (27).
A semimechanistic population pharmacokinetic/pharmacodynamic model was created to evaluate alternative schedules and predicted that intermittent dosing could prevent prolonged accumulation (26). The modeling study also demonstrated similar results for 500 mg on a 5-days-on/2-days-off schedule compared with the 400-mg continuous daily dosing identified as the MTD in a prior study (27) . For this reason, the intermittent schedule was selected for analysis in this study, and the results demonstrate that it provided comparable but controllable exposure.
The results of this phase I study suggest that dovitinib may offer clinical benefit in patients who have failed prior VEGF-targeted and mTOR inhibitor therapies, a population that is particularly difficult to treat due to the lack of standard therapeutic options following disease progression. In this study 80% and 55% of patients had received at least 1 prior VEGF pathway inhibitor and at least 1 prior mTOR pathway inhibitor, respectively, and 50% of patients received inhibitors of both pathways. These results were further explored in the phase II dose-expansion component of this study (in patients previously treated with VEGF and mTOR inhibitors; ref. (24)). In addition, 
dovitinib is currently being investigated in the phase III study (NCT01223027) of dovitinib vs. sorafenib in patients with metastatic RCC following failure on no more than 1 VEGF pathway-targeted therapy and no more than 1 mTOR-targeted therapy.
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